Prof Stephen Gillespie

Prof Stephen Gillespie
Sir James Black Chair of Medicine

data source: symbiosis

Research Overview from research@st-andrews

Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti tuberculosis agents. His main research activity is in the area of tuberculosis drug development.

For the last twenty years Stephen Gillespie has been involved in various aspects of  tuberculosis drug development. This has included the evaluation of new candidate antituberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He is also one of the three Chief Investigators of the PanACEA consortium that is developing Europe and Africa's clinical trials capacity.

source: research@st-andrews
Recent publications listed in research@st-andrews
Muliaditan, M, Davies, GR, Simonsson, USH, Gillespie, SH & Pasqua, OD 2017, 'The implications of model–informed drug discovery and development for tuberculosis' Drug Discovery Today, vol 22, no. 3, pp. 481-486. DOI: 10.1016/j.drudis.2016.09.004
Boeree, MJ, Heinrich, N, Aarnoutse, R, Diacon, AH, Dawson, R, Rehal, S, Kibiki, GS, Churchyard, G, Sanne, I, Ntinginya, NE, Minja, LT, Hunt, RD, Charalambous, S, Hanekom, M, Semvua, HH, Mpagama, SG, Manyama, C, Mtafya, B, Reither, K, Wallis, RS, Venter, A, Narunsky, K, Mekota, A, Henne, S, Colbers, A, Plemper van Balen, G, Gillespie, SH, Phillips, PPJ & Hoelscher, M 2017, 'High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial' Lancet Infectious Diseases, vol 17, no. 1, pp. 39-49. DOI: 10.1016/S1473-3099(16)30274-2, 10.1016/S1473-3099(16)30274-2
Gillespie, SH, Sabiiti, W & Oravcova, K 2017, Mycobacterial load assay. in KA Bishop-Lilly (ed.), Diagnostic Bacteriology: Methods and Protocols. Methods in Molecular Biology, vol. 1616, Humana Press/Springer, New York, NY, pp. 89-105. DOI: 10.1007/978-1-4939-7037-7_5
Sabiiti, W, Mtafya, B, Kuchaka, D, Azam, K, Viegas, S, Mdolo, A, Farmer, E, Khonga, M, Evangelopoulos, D, Honeyborne, I, Rachow, A, Heinrich, N, Ntinginya, NE, Bhatt, N, Davies, GR, Jani, IV, McHugh, TD, Kibiki, G, Hoelscher, M, Gillespie, SH & on behalf of the PANBIOME (Pan-African Biomarker Expansion Programme) consortium 2016, 'Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings' International Journal of Tuberculosis and Lung Disease, vol 20, no. 8, pp. 1004-1009. DOI: 10.5588/ijtld.15.0951
Lipworth, S, Hammond, RJH, Baron, VO, Hu, Y, Coates, A & Gillespie, SH 2016, 'Defining dormancy in mycobacterial disease' Tuberculosis, vol 99, pp. 131-142. DOI: 10.1016/
Boeree, MJ, Gillespie, SH, Hoelscher, M & PanACEA core team 2016, 'Therapy for Tuberculous Meningitis' New England Journal of Medicine, vol 374, no. 22, pp. 2187-8. DOI: 10.1056/NEJMc1602291#SA2
Honeyborne, I, McHugh, TD, Kuittinen, I, Cichonska, A, Evangelopoulos, D, Ronacher, K, van Helden, PD, Gillespie, SH, Fernandez-Reyes, D, Walzl, G, Rousu, J, Butcher, PD & Waddell, SJ 2016, 'Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy' BMC Medicine, vol 14, no. 1, pp. 1-13. DOI: 10.1186/s12916-016-0609-3
Phillips, PPJ, Dooley, KE, Gillespie, SH, Heinrich, N, Stout, JE, Nahid, P, Diacon, AH, Aarnoutse, RE, Kibiki, GS, Boeree, MJ & Hoelscher, M 2016, 'A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)' BMC Medicine, vol 14, 51, pp. 1-11. DOI: 10.1186/s12916-016-0597-3
Donald, I, Meyer, K, Gillespie, SH, Bowness, R & Brengman, J 2015, Project Sanitarium: gaming TB - A serious game for a serious problem. in 7th International Conference on Games and Virtual Worlds for Serious Applications, VS-Games 2015., 7295782, IEEE, Seventh International Conference on Virtual Worlds and Games for Serious Applications: VS-Games 2015, University of Skövde, Sweden, 16-18 September. DOI: 10.1109/VS-GAMES.2015.7295782
Boeree, MJ, Diacon, AH, Dawson, R, Narunsky, K, du Bois, J, Venter, A, Phillips, PPJ, Gillespie, SH, McHugh, TD, Hoelscher, M, Heinrich, N, Rehal, S, van Soolingen, D, van Ingen, J, Magis-Escurra, C, Burger, D, Plemper van Balen, G & Aarnoutse, RE 2015, 'A Step toward an Optimized Rifampin Dose Completed' American Journal of Respiratory and Critical Care Medicine, vol 192, no. 4, pp. 525-6. DOI: 10.1164/rccm.201506-1061LE
Honeyborne, I, Lipman, MC, Eckold, C, Evangelopoulos, D, Gillespie, SH, Pym, A & McHugh, TD 2015, 'Effective anti-tuberculosis therapy correlates with plasma small RNA' European Respiratory Journal, vol 45, no. 6, pp. 1741-1744. DOI: 10.1183/09031936.00221214
Boeree, MJ, Diacon, AH, Dawson, R, Narunsky, K, du Bois, J, Venter, A, Phillips, PPJ, Gillespie, SH, Mc Hugh, TD, Hoelscher, M, Heinrich, N, Rehal, S, van Soolingen, D, van Ingen, J, Magis-Escurra, C, Burger, D, Plemper van Balen, G & Aarnoutse, RE 2015, 'A dose ranging trial to optimize the dose of Rifampin in the treatment of tuberculosis' American Journal of Respiratory and Critical Care Medicine, vol 191, no. 9, pp. 1058-1065. DOI: 10.1164/rccm.201407-1264OC
Gillespie, SH, Mendel, CM, Phillips, PPJ & REMoxTB Consortium 2015, 'Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis' New England Journal of Medicine, vol 372, no. 6, pp. 577-577. DOI: 10.1056/NEJMc1414718
Gillespie, SH, Ling, CL, Oravcova, K, Pinheiro, M, Wells, L, Bryant, JM, McHugh, TD, Bébéar, C, Webster, D, Harris, SR, Seth-Smith, HMB & Thomson, NR 2015, 'Genomic investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen' Clinical Infectious Diseases, vol 60, no. 3, pp. 381-388. DOI: 10.1093/cid/ciu820
Bowness, R, Boeree, MJ, Aarnoutse, R, Dawson, R, Diacon, A, Mangu, C, Heinrich, N, Ntinginya, NE, Kohlenberg, A, Mtafya, B, Phillips, PPJ, Rachow, A, Plemper van Balen, G & Gillespie, SH 2015, 'The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations' Journal of Antimicrobial Chemotherapy, vol 70, no. 2, pp. 448-455. DOI: 10.1093/jac/dku415
Heinrich, N, Dawson, R, du Bois, J, Narunsky, K, Horwith, G, Phipps, AJ, Nacy, CA, Aarnoutse, RE, Boeree, MJ, Gillespie, SH, Venter, A, Henne, S, Rachow, A, Phillips, PPJ, Hoelscher, M, Diacon, AH & on behalf of the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) 2015, 'Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients' Journal of Antimicrobial Chemotherapy. DOI: 10.1093/jac/dku553